Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs State Street SPDR Bloomberg High Yield Bond ETF (JNK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs State Street SPDR Bloomberg High Yield Bond ETF — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while State Street SPDR Bloomberg High Yield Bond ETF trades at $95.85. The key difference: State Street SPDR Bloomberg High Yield Bond ETF is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | JNK | |
|---|---|---|
Market Cap | $39.89B | — |
Sector | Health | Fixed Income |
52-Week High | $491.22 | $98.19 |
52-Week Low | $278.09 | $94.66 |
Enterprise Value | $38.15B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
JNK trades at $95.93, down 0.07% on the day, with a bearish technical signal from moving averages and oscillators showing neutral readings. The ETF has declared dividends for 2026, including $0.53 for H2-26. Recent news highlights strong bond ETF inflows amid inflation fears and potential Fed rate hikes, creating a volatile backdrop for high-yield bonds.
Outlook remains cautious due to bearish technicals and macroeconomic uncertainty. Opportunities exist for yield-seeking investors, but risks include interest rate sensitivity and fund fees. Investors should weigh the ETF's high-yield exposure against potential headwinds from rising rates and economic shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About State Street SPDR Bloomberg High Yield Bond ETF
JNK is a major ETF tracking the Bloomberg High Yield Very Liquid Index. It provides exposure to U.S. dollar-denominated junk bonds with above-average liquidity, featuring 2026 top holdings like EchoStar, Cloud Software Group, and Carnival Corp.
Read more on JNK →
